Jazz Pharmaceuticals (JAZZ) Q1 2026 Earnings
How Did JAZZ Stock React to Q1 2026 Earnings?
S&P 500 over the same 30 days: +0.73%.
Did JAZZ Beat Earnings? Q1 2026 Results
Yes. Jazz Pharmaceuticals reported Q1 2026 earnings of $6.34 a share on May 5, 2026, beating the $4.66 consensus estimate by 36.2%. Revenue was $1.1B against a $979.0M estimate.
Jazz Pharmaceuticals delivered a standout first quarter for fiscal 2026, posting non-GAAP adjusted EPS of $6.34 against a consensus estimate of $4.66, a beat of 36.18%, while revenue climbed 19.1% year-over-year to $1.07 billion, exceeding analyst expectations of $979.01 million by 9.18%. The headline driver behind the earnings strength was broad commercial momentum across the company's core franchises, with Xywav contributing $408.20 million as the largest single revenue source, Epidiolex growing 15% to $249.80 million, and Zepzelca surging 60% to $101.00 million on the strength of its atezolizumab combination in small cell lung cancer. A $122.80 million gain from the sale of a Rare Pediatric Disease Priority Review Voucher further supported GAAP results, helping swing net income to $293.10 million from a loss of $92.50 million a year ago. Shares reached notable highs in the wake of the report, reflecting investor confidence in Jazz's diversified portfolio. Management reaffirmed full-year 2026 revenue guidance of $4.25 billion to $4.50 billion, with a potential zanidatamab approval in gastroesophageal adenocarcinoma carrying a PDUFA date of August 25, 2026.
- Strong Xywav demand with 425 net patient adds reaching ~16,600 active patients
- Zepzelca revenues grew 60% YoY driven by uptake of Zepzelca and atezolizumab combination in 1LM ES-SCLC
- Epidiolex continued consistent demand-driven growth of 15% YoY
- Modeyso contributed $41 million in its first full quarter following August 2025 launch
- SG&A declined significantly due to $172 million Xyrem antitrust litigation settlements in 1Q25 not recurring
- $122.8 million gain on sale of Priority Review Voucher
“Our first-quarter results reflect disciplined execution across the business, delivering 19% year-over-year growth alongside key pipeline advancements and positioning the company for an outstanding 2026.”
Jazz Pharmaceuticals CEO, on the earnings call
What Was Jazz Pharmaceuticals's Outlook in Q1 2026?
Jazz Pharmaceuticals reaffirmed its full-year 2026 revenue guidance of $4,250 million to $4,500 million. The company also reaffirmed expense guidance: GAAP gross margin of 89%-90%, GAAP SG&A of $1,424-$1,497 million, GAAP R&D of $811-$867 million, and GAAP effective tax rate of 0%-10%. Non-GAAP gross margin is guided at 90%-91%, non-GAAP SG&A of $1,260-$1,320 million, non-GAAP R&D of $725-$775 million, and non-GAAP effective tax rate of 11.5%-13.5%. Weighted-average shares outstanding guidance was updated to 66-67 million. The company expects second-line Zepzelca use to decline throughout the year. The zanidatamab sBLA in 1L HER2+ GEA has a PDUFA date of August 25, 2026, with potential approval and launch on or before that date. The Phase 3 ACTION trial for Modeyso has a top-line readout expected late 2026/early 2027.
JAZZ YoY Financials
| Metric | Q1 2026 | Q1 2025 | Year over year |
|---|---|---|---|
| Revenue | $1.1B | $897.9M | +19.1% |
| Net Income | $293.1M | $56.7M | +416.7% |
| Operating Income | $336.6M | $42.0M | +702.2% |
JAZZ Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.